Thomas E MÃ¼rdter

List of Publications by Year
in descending order

69 papers	**2,997** citations	186265 **28** h-index	168389 **53** g-index
70 all docs	**70** docs citations	**70** times ranked	**4054** citing authors

#	Article	IF	Citations
1	Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Annals of Surgical Oncology, 2014, 21, 553-559.	1.5	287
2	Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clinical Pharmacology and Therapeutics, 2011, 89, 708-717.	4.7	241
3	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 189-197.	2.5	236
4	Fate of the Antibiotic Sulfamethoxazole and Its Two Major Human Metabolites in a Water Sediment Test. Environmental Science & Technology, 2009, 43, 3135-3141.	10.0	170
5	Pharmacogenomics of Tamoxifen Therapy. Clinical Chemistry, 2009, 55, 1770-1782.	3.2	142
6	P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clinical Pharmacology and Therapeutics, 2003, 73, 223-231.	4.7	139
7	The influence ofCYP2B6,CYP2C9andCYP2D6genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology, 2002, 54, 157-167.	2.4	118
8	Role of P-Glycoprotein Inhibition forÂDrug Interactions. Clinical Pharmacokinetics, 2007, 46, 1039-1049.	3.5	101
9	Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer, 2006, 6, 86.	2.6	89
10	Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib. Clinical Pharmacokinetics, 2003, 42, 283-292.	3.5	78
11	Expression and function of Î²-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 362, 110-115.	3.0	73
12	Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. Clinical Pharmacology and Therapeutics, 2002, 71, 479-487.	4.7	73
13	Increased??Absorption??of??Digoxin from??the??Human??Jejunum Due??to??Inhibition??of??Intestinal Transporter-Mediated Efflux. Clinical Pharmacokinetics, 2007, 46, 777-785.	3.5	64
14	Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Research, 2016, 76, 2868-2875.	0.9	63
15	Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer, 2008, 8, 364.	2.6	58
16	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Frontiers in Pharmacology, 2017, 8, 582.	3.5	52
17	Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by Î²-Glucuronidase. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 223-228.	2.5	51
18	Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. The Histochemical Journal, 2001, 33, 329-336.	0.6	47

#	Article	IF	Citations
19	P-glycoprotein-mediated transport of digitoxin, α-methyldigoxin and β-acetyldigoxin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 337-343.	3.0	43
20	Population pharmacokinetics of oral busulfan in children. Cancer Chemotherapy and Pharmacology, 2003, 52, 209-216.	2.3	43
21	A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 1017-1024.	3.3	42
22	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Human Molecular Genetics, 2012, 21, 1145-1154.	2.9	37
23	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor. Analytical and Bioanalytical Chemistry, 2015, 407, 6815-6825.	3.7	35
24	Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 768, 255-260.	2.3	32
25	Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respiratory Research, 2005, 6, 21.	3.6	32
26	Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Research, 2007, 27, 2131-9.	1.1	31
27	Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Lung Cancer, 2010, 68, 346-354.	2.0	29
28	Simulation with cells *in vitro* of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. British Journal of Pharmacology, 2014, 171, 5624-5635.	5.4	29
29	Induction of Metallothionein in Proximal Tubular Cells by Zinc and Its Potential as an Endogenous Antioxidant. Kidney and Blood Pressure Research, 2005, 28, 127-133.	2.0	28
30	Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2′-O-methyl-RNA. International Journal of Pharmaceutics, 2011, 419, 33-42.	5.2	28
31	Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Laboratory Investigation, 2005, 85, 1565-1569.	3.7	26
32	Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin. Cancer Research, 2012, 72, 5824-5832.	0.9	25
33	Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. Analytical and Bioanalytical Chemistry, 2012, 403, 301-308.	3.7	24
34	Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anti-Cancer Drugs, 2005, 16, 337-344.	1.4	23
35	Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up. Journal of Clinical Oncology, 2001, 19, 3-9.	1.6	22
36	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology, 2003, 57, 105-111.	2.4	21

#	Article	IF	Citations
37	TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Research and Treatment, 2007, 107, 15-24.	2.5	21
38	Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites. Frontiers in Pharmacology, 2019, 10, 530.	3.5	21
39	Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 791, 371-380.	2.3	18
40	The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Archives of Toxicology, 2018, 92, 1099-1112.	4.2	18
41	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology and Therapeutics, 2020, 108, 661-670.	4.7	17
42	Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death and Differentiation, 2020, 27, 3037-3052.	11.2	17
43	Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. Journal of Clinical Oncology, 2019, 37, 1981-1982.	1.6	16
44	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clinical Cancer Research, 2020, 26, 6523-6534.	7.0	16
45	Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue. Biomedical Applications, 1998, 709, 289-295.	1.7	15
46	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. Therapeutic Drug Monitoring, 2006, 28, 559-567.	2.0	15
47	Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 7497-7502.	3.7	15
48	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. Analytica Chimica Acta, 2020, 1134, 125-135.	5.4	15
49	Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography–electrospray ionization–tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 400, 3429-3441.	3.7	14
50	Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. British Journal of Pharmacology, 2022, 179, 2906-2924.	5.4	14
51	Efficient Telomerase Inhibition in Human Non-small Cell Lung Cancer Cells by Liposomal Delivery of 2′-O-Methyl-RNA. Journal of Pharmaceutical Sciences, 2009, 98, 1765-1774.	3.3	13
52	Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: Is there any prognostic relevance?. Acta Histochemica, 1999, 101, 239-253.	1.8	11
53	Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring. Cancers, 2021, 13, 5682.	3.7	11
54	Impact of mistletoe lectin binding in breast cancer. Anticancer Research, 2004, 24, 1187-92.	1.1	11

#	Article	IF	Citations
55	Unchanged serum levels of advanced glycation endproducts in patients with liver disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 375, 401-406.	3.0	10
56	Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget, 2016, 7, 53526-53539.	1.8	9
57	The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition, 2013, 41, 1906-1913.	3.3	8
58	Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-β-glucuronide. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1153-1158.	1.0	7
59	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. Analytica Chimica Acta, 2022, 1202, 339661.	5.4	7
60	Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. Molecular Cancer Therapeutics, 2022, 21, 799-809.	4.1	7
61	Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. Talanta, 2021, 221, 121658.	5.5	6
62	Syntheses of 2H-labelled dihydropyrimidinediones and their metabolites. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 7-11.	1.0	5
63	Expression of active human β-glucuronidase in Sf9 cells infected with recombinant baculovirus. Life Sciences, 2002, 71, 1547-1557.	4.3	5
64	Synthesis of [2H3]-labelled sulfamethoxazole and its main urinary metabolites. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 656-659.	1.0	5
65	Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine. European Journal of Clinical Pharmacology, 2010, 66, 1-3.	1.9	4
66	Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem. Anticancer Research, 2018, 38, 1585-1593.	1.1	4
67	Synthesis of [2H]-labelled phase-I-metabolites using 1-[2H]-pyridinium hydrochloride. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 457-461.	1.0	3
68	A new [^{2}H]–labelled α–trichloroimidate glucuronic ester for the synthesis of deuterated drug conjugates. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 699-703.	1.0	3
69	(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. Journal of Personalized Medicine, 2022, 12, 511.	2.5	3